#Denmark #Roche Diagnostics #Nordic Bioscience #PRO-C3 #Herlev

Nordic Bioscience Unveils Revolutionary PRO-C3 Test by Roche Diagnostics

In a significant advancement for liver disease assessment, Nordic Bioscience has officially launched the Elecsys PRO-C3 test through Roche Diagnostics on the cobas analysers. This major announcement, made in Herlev, Denmark, on May 8, 2025, marks a pivotal development in the field of liver healthcare, particularly in evaluating the severity of liver fibrosis.

The Roche Elecsys® PRO-C3 test employs the innovative ADAPT formula, which takes into account age, diabetes status, PRO-C3 levels, and platelet counts to accurately assess liver fibrosis. Liver fibrosis is a grave condition that, according to the World Health Organization, accounts for approximately one in every 25 deaths globally. With this new test, healthcare professionals have access to a powerful tool for diagnosing this silent disease.

A Leading Biomarker for Precision Medicine

The PRO-C3 biomarker is validated at Nordic Bioscience’s CAP-CLIA certified laboratories in Denmark, illustrating the company's commitment to precision medicine. The company's dedication is evidenced by its extensive body of scientific literature, having published over 250 research articles related to PRO-C3 and associated fibrotic diseases over the last decade. This positions Nordic Bioscience as a global leader in this field.

As the first biomarker from Nordic Bioscience's fibrosis panel to receive CE approval, PRO-C3 addresses a critical need in the medical community, as fibrotic alterations in organs such as the liver contribute significantly to mortality rates in the Western world. Morten Karsdal, CEO of Nordic Bioscience, commented on the launch, stating, “The Elecsys PRO-C3 test is the first product to emerge from our collaboration with Roche Diagnostics. We take pride in making our technology globally accessible to positively impact patients’ lives.”

Innovations and Developments

Prior to this launch, the PRO-C3 biomarker was available exclusively through the nordicPRO-C3™ laboratory service based in Denmark. The current Elecsys PRO-C3 test has been developed under a licensing agreement between Nordic Bioscience and Roche Diagnostics, marking a transformative step in the commercial availability of this vital diagnostic tool.

For further details regarding PRO-C3, including scientific insights and clinical applications, visit the Nordic Bioscience website at Nordic Bioscience - PRO-C3.

About Nordic Bioscience

Nordic Bioscience, headquartered in Herlev, Denmark, specializes in the development of biomarkers utilizing unique neoepitope technology. By integrating preclinical and clinical research expertise, the company aims to create biomarkers that facilitate rapid and objective decision-making in trial developments while enhancing patient care in diagnostics.

For more information about the company, visit Nordic Bioscience Official Site. For product inquiries, feel free to contact us.

This launch exemplifies Nordic Bioscience's commitment to advancing healthcare solutions, and with the Elecsys PRO-C3 test, they are poised to make a significant difference in the management of liver diseases.